Neuroone Medical Technologies (NMTC) Corporate presentation summary

Technology and product innovation

• Developed thin-film, flexible electrodes for brain and nerve applications, enabling both diagnostic and therapeutic use with a single device.

• Achieved 510(k) FDA clearance for four product families, including the OneRF Trigeminal Nerve Ablation System.

• Product portfolio includes Evo Cortical and SEEG Electrodes, OneRF Ablation Systems, and a drug delivery system in development.

• SEEG-based drug delivery system allows simultaneous brain activity recording and drug administration, with successful preclinical testing.

• Spinal cord paddle lead offers broader stimulation coverage and reduced battery usage, targeting a $3B+ global market.

Strategic partnerships and collaborations

• Exclusive partnership with Zimmer Biomet for distribution and commercialization, including a $3M licensing fee and expanded rights.

• Collaboration with Mayo Clinic since 2015, with leading neurologists on the advisory board and ongoing clinical research.

• Distribution discussions underway for the OneRF Trigeminal Nerve Ablation System with potential strategic partners.

• Interest from pharmaceutical companies for the drug delivery platform, with initial device sales for preclinical testing.

Market opportunity and financial performance

• Addressing multi-billion dollar markets in epilepsy, Parkinson’s, pain management, and drug delivery.

• FY2025 product revenue reached $9.1M, a 163% increase over FY2024, with a gross margin of 56.5%.

• Total 2025 revenue, including a $3M licensing payment, was $12.1M.

• Debt-free balance sheet with $6.6M in cash as of September 2025.

• New partnerships and licensing agreements expected to drive further revenue growth.